News Search Results
Mar 03, 2026, 22:49 ET MGI Tech Announces Acquisition of STOmics and CycloneSEQ to Deliver Integrated Long-Read, Short-Read and Spatial Omics Solutions
focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology.We provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare and
More news about: MGI TECH
Mar 03, 2026, 21:56 ET Advancing Influenza Vaccine Development: Sino Biological Launches Antigens for the 2026-2027 Northern Hemisphere Influenza Vaccine Strains
preparedness," said Dr. Rob Burgess, Chief Business Officer at Sino Biological US.About Sino BiologicalSino Biological is a global biotechnology company specializing in high-quality recombinant proteins, antibodies, and customized research services. Serving researchers in more than 90 countries,
More news about: Sino Biological, Inc.
Mar 03, 2026, 21:00 ET Gene Solutions Announces Strategic Entry into Türkiye with Robust Real-World Evidence at the 2nd International Hereditary Cancers Congress 2026
in asymptomatic adults. BMC Medicine, 23(1).About Gene SolutionsGene Solutions is a global biotechnology company headquartered in Singapore with a mission to make advanced genomic solutions accessible and affordable. Leveraging multi-omics, Next-Generation
More news about: Gene Solutions Genomics Pte Ltd
Mar 03, 2026, 20:53 ET Advancing Influenza Vaccine Development: Sino Biological Launches Antigens for the 2026-2027 Northern Hemisphere Influenza Vaccine Strains
preparedness," said Dr. Rob Burgess, Chief Business Officer at Sino Biological US.About Sino BiologicalSino Biological is a global biotechnology company specializing in high-quality recombinant proteins, antibodies, and customized research services. Serving researchers in more than 90 countries,
More news about: Sino Biological, Inc.
Mar 03, 2026, 16:01 ET Kewaunee Scientific and Nu Aire Inc. to Attend analytica 2026 in Munich
environments worldwide.Established in 1968, analytica is the leading global trade fair for laboratory, technology, analysis, and biotechnology. The 2026 trade show and conference is expected to bring together over 30,000 lab professionals, planners, and industry leaders to explore advances
More news about: Kewaunee Scientific Corporation
Mar 03, 2026, 16:01 ET Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Calif., March 3, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the fourth quarter and year ended December 31, 2025, including
More news about: Rigel Pharmaceuticals, Inc.
Mar 03, 2026, 14:36 ET Hematologic Malignancies Market to Reach USD 128.48 Billion by 2032, Driven by Immunotherapy, CAR-T, and Precision Oncology - Credence Research Inc.
2024. The region's growth is supported by increasing awareness of hematologic cancers, strong public healthcare systems, and rising investment in biotechnology and pharmaceutical research. Countries such as Germany, France, and the U.K. are at the forefront of oncology innovation, with numerous ongoing
More news about: Credence Research Inc.
Mar 03, 2026, 12:12 ET Longevity Medical Institute® Opens Federally Licensed Stem Cell and Regenerative Medicine Biotechnology Laboratory in Los Cabos
/PRNewswire/ -- Longevity Medical Institute® today announced the opening of its federally licensed Stem Cell and Regenerative Medicine Biotechnology Laboratory, further expanding what is now one of the most comprehensive regenerative and advanced diagnostic medical campuses in Los Cabos.
More news about: Longevity Medical Institute LLC
Mar 03, 2026, 11:00 ET bitBiome Announces Major Collaboration Agreement in Commercial-Scale Bio-Manufacturing of Food-Grade Ingredient
to advance next generation biomanufacturing solutions designed for global industrial deployment.About bitBiomebitBiome is a biotechnology company unlocking the full potential of our planet's microbes to power the future of the bioeconomy. bitBiome's platform is built on their proprietary
More news about: bitBiome
Mar 03, 2026, 10:02 ET Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them
using encapsulated cell-based therapies.Following its recent rebrand from Avant Technologies, Avaí Bio has fully pivoted to biotechnology, concentrating on sourcing, developing, and protecting advanced cellular therapies through strategic joint ventures and licensing agreements. The
More news about: USA News Group
Mar 03, 2026, 09:25 ET Insilico Medicine and Liquid AI Announce Strategic Partnership Delivering Lightweight Scientific Foundation Models for Drug Discovery
liquid.ai.About Insilico Medicine: Insilico Medicine is a clinical-stage biotechnology company using AI for drug development across cancer, fibrosis, immunity, central nervous system diseases, and aging-related conditions. The company's
More news about: Insilico Medicine; Liquid AI
Mar 03, 2026, 09:00 ET Protego Biopharma Appoints John M. Maraganore, Ph.D., to Board of Directors
SAN DIEGO, March 3, 2026 /PRNewswire/ -- Protego Biopharma, Inc., a clinical-stage biotechnology company dedicated to pioneering first-in-class small molecule therapeutics that reprogram protein folding to address systemic amyloid diseases and
More news about: Protego Biopharma
Mar 03, 2026, 09:00 ET Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone
(OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced—together with its joint venture partner and global biotechnology firm, Austrianova—the initiation of production for
More news about: Market News Updates
Mar 03, 2026, 09:00 ET ALORA Appoints Adam Helms as CEO; Secures Funding from Grantham Environmental Trust and Toyota Ventures
NORWICH RESEARCH PARK, England, March 3, 2026 /PRNewswire/ -- ALORA, an agricultural biotechnology company developing gene-edited crop traits that redirect plant energy from stress defense to yield, today announced the appointment of Adam Helms
More news about: ALORA Innovations Inc.
Mar 03, 2026, 09:00 ET ALORA Appoints Adam Helms as CEO; Secures Funding from Grantham Environmental Trust and Toyota Ventures
NORWICH RESEARCH PARK, England, March 3, 2026 /PRNewswire/ -- ALORA, an agricultural biotechnology company developing gene-edited crop traits that redirect plant energy from stress defense to yield, today announced the appointment of Adam Helms
More news about: ALORA Innovations Inc.
Mar 03, 2026, 08:50 ET Draper Joins SCALE Team to Improve Indoor Air Quality and Human Health Using Smart Building Systems as Part of ARPA-H-Funded Project
deliver clean air where it's needed within the building to reduce exposures."Our SCALE project represents a convergence of advanced biotechnology and intelligent infrastructure to create the world's first truly health-responsive built environment," said Sam Molyneux, overall lead for the SCALE
More news about: Draper Laboratory
Mar 03, 2026, 08:30 ET Avaí Bio and Austrianova Begin Production of Master Cell Bank for Klotho Anti-Aging Therapy Under GMP Standards
(OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced—together with its joint venture partner and global biotechnology firm, Austrianova—the initiation of production for
More news about: Avaí Bio, Inc.
Mar 03, 2026, 08:00 ET Penn Engineering & UL Research Institutes Partner for Educator Fellowship
close proximity to Penn's other schools, including Medicine, Law, Business, and Design enables and promotes interdisciplinary collaboration. From biotechnology and nanotechnology to artificial intelligence and robotics, Penn Engineering's research is at the forefront of scientific and technological frontiers.About
More news about: UL Research Institutes
Mar 03, 2026, 07:00 ET SpliSense Granted EMA EARLY PRIME Designation for SPL84 in Cystic Fibrosis
March 3, 2026 /PRNewswire/ -- SpliSense, a clinical-stage biotechnology company developing transformative RNA-based therapies for pulmonary diseases, today announced that the European Medicines Agency (EMA) has granted
More news about: Splisense
Mar 03, 2026, 07:00 ET Matricelf Ltd. (TASE: MTLF) Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy
NESS ZIONA, Israel, March 3, 2026 /PRNewswire/ -- Matricelf Ltd. (TASE: MTLF), a biotechnology company developing autologous engineered tissue therapies, today announced that it has signed a Memorandum of Understanding, subject to the execution
More news about: Matricelf Ltd.
Mar 03, 2026, 06:30 ET Immunic to Participate in Investor Conferences in March
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced participation in the following
More news about: Immunic, Inc.
Mar 02, 2026, 20:00 ET Efor strengthens its presence in Asia with the acquisition of No deviation
compliance for Life Sciences industries. With more than 3,000 professionals operating across 18 countries, the group supports global pharmaceutical, biotechnology and medical device leaders.
More news about: Efor
Mar 02, 2026, 17:58 ET REGENXBIO, Inc. Stockholders Have Rights - Stockholders Who Lost Money Investing in RGNX Should Contact Robbins LLP for Information About Recovering Their Losses
purchased or otherwise acquired REGENXBIO, Inc. (NASDAQ: RGNX) securities between February 9, 2022 and January 27, 2026. REGENXBIO is a clinical-stage biotechnology company providing gene therapies that deliver functional genes to cells with genetic defects in the United States.
More news about: Robbins LLP
Mar 02, 2026, 17:46 ET Global Implanted Brain-Computer Interface Devices Market to Observe Stupendous Growth at a CAGR of ~10% by 2032 | DelveInsight
products.Greater public awareness and acceptance of neuroprosthetics and assistive technologies.Technological convergence (biotechnology, nanotechnology, robotics), enabling more effective and scalable implanted BCI devices.Regional Implanted Brain-Computer Interface
More news about: DelveInsight Business Research LLP
Mar 02, 2026, 17:00 ET Congruence and Ono Pharma Expand Multi-Target Research Partnership with the Addition of Two New Programs
readily scalable and repeatable value creation paradigm.About Congruence TherapeuticsCongruence is a computationally driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Our proprietary
More news about: Congruence Therapeutics